Analyst Price Target is $26.00
▲ +57.10% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CollPlant Biotechnologies in the last 3 months. The average price target is $26.00, with a high forecast of $26.00 and a low forecast of $26.00. The average price target represents a 57.10% upside from the last price of $16.55.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in CollPlant Biotechnologies. This Buy consensus rating has held steady for over two years.
CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. It's products include VergenixSTR, VergenixFG, and CollPlant Surgical Matrix. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.